{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:42:00Z","timestamp":1789011720874,"version":"build-2803163510"},"reference-count":129,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T00:00:00Z","timestamp":1614902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41409-021-01246-5","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T15:04:25Z","timestamp":1614956665000},"page":"1518-1534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Contemporary haploidentical stem cell transplant strategies in children with hematological malignancies"],"prefix":"10.1038","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-6503","authenticated-orcid":false,"given":"Ravi M.","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"1246_CR1","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097\u20132100. https:\/\/doi.org\/10.1126\/science.1068440","journal-title":"Science"},{"key":"1246_CR2","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","volume":"23","author":"F Aversa","year":"2005","unstructured":"Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:3447\u201354. https:\/\/doi.org\/10.1200\/JCO.2005.09.117","journal-title":"J Clin Oncol"},{"key":"1246_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/sj.bmt.1702996","volume":"27","author":"R Handgretinger","year":"2001","unstructured":"Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A, et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transpl. 2001;27:777\u201383. https:\/\/doi.org\/10.1038\/sj.bmt.1702996","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR4","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2018.02.005","volume":"24","author":"H Elmariah","year":"2018","unstructured":"Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non-first-degree related donors. Biol Blood Marrow Transpl. 2018;24:1099\u2013102. https:\/\/doi.org\/10.1016\/j.bbmt.2018.02.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","volume":"141","author":"RM Shah","year":"2018","unstructured":"Shah RM, Elfeky R, Nademi Z, Qasim W, Amrolia P, Chiesa R, et al. T-cell receptor alphabeta(+) and CD19(+) cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency. J Allergy Clin Immunol. 2018;141:1417\u201326 e1411. https:\/\/doi.org\/10.1016\/j.jaci.2017.07.008","journal-title":"J Allergy Clin Immunol"},{"key":"1246_CR6","doi-asserted-by":"publisher","first-page":"e13546","DOI":"10.1111\/petr.13546","volume":"23","author":"V Uygun","year":"2019","unstructured":"Uygun V, Karasu G, Daloglu H, Ozturkmen S, Caki Kilic S, Hazar V, et al. Haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide in high-risk children: a single-center study. Pediatr Transpl. 2019;23:e13546. https:\/\/doi.org\/10.1111\/petr.13546","journal-title":"Pediatr Transpl"},{"key":"1246_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","volume":"55","author":"SO Ciurea","year":"2020","unstructured":"Ciurea SO, Al Malki MM, Kongtim P, Fuchs EJ, Luznik L, Huang XJ, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:12\u201324. https:\/\/doi.org\/10.1038\/s41409-019-0499-z","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","volume":"124","author":"Y Wang","year":"2014","unstructured":"Wang Y, Chang YJ, Xu LP, Liu KY, Liu DH, Zhang XH, et al. Who is the best donor for a related HLA haplotype-mismatched transplant? Blood. 2014;124:843\u201350. https:\/\/doi.org\/10.1182\/blood-2014-03-563130","journal-title":"Blood"},{"key":"1246_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"A Emadi","year":"2009","unstructured":"Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol. 2009;6:638\u201347. https:\/\/doi.org\/10.1038\/nrclinonc.2009.146","journal-title":"Nat Rev Clin Oncol"},{"key":"1246_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","volume":"14","author":"L Luznik","year":"2008","unstructured":"Luznik L, O\u2019Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2008;14:641\u201350. https:\/\/doi.org\/10.1016\/j.bbmt.2008.03.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/MOH.0b013e32833eaf1b","volume":"17","author":"L Luznik","year":"2010","unstructured":"Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010;17:493\u20139. https:\/\/doi.org\/10.1097\/MOH.0b013e32833eaf1b","journal-title":"Curr Opin Hematol"},{"key":"1246_CR12","doi-asserted-by":"publisher","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","volume":"5","author":"CG Kanakry","year":"2013","unstructured":"Kanakry CG, Ganguly S, Zahurak M, Bolanos-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157 https:\/\/doi.org\/10.1126\/scitranslmed.3006960","journal-title":"Sci Transl Med"},{"key":"1246_CR13","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","volume":"124","author":"S Ganguly","year":"2014","unstructured":"Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, et al. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014;124:2131\u201341. https:\/\/doi.org\/10.1182\/blood-2013-10-525873","journal-title":"Blood"},{"key":"1246_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","volume":"131","author":"A Russo","year":"2018","unstructured":"Russo A, Oliveira G, Berglund S, Greco R, Gambacorta V, Cieri N, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131:247\u201362. https:\/\/doi.org\/10.1182\/blood-2017-05-780668","journal-title":"Blood"},{"key":"1246_CR15","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1182\/blood.V85.10.2742.bloodjournal85102742","volume":"85","author":"RJ Jones","year":"1995","unstructured":"Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995;85:2742\u20136.","journal-title":"Blood"},{"key":"1246_CR16","first-page":"363","volume":"18","author":"H Mayumi","year":"1986","unstructured":"Mayumi H, Himeno K, Tokuda N, Nomoto K. Drug-induced tolerance to allografts in mice. VII. Optimal protocol and mechanism of cyclophosphamide-induced tolerance in an H-2 haplotype-identical strain combination. Transpl Proc. 1986;18:363\u20139.","journal-title":"Transpl Proc"},{"key":"1246_CR17","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","volume":"8","author":"PV O\u2019Donnell","year":"2002","unstructured":"O\u2019Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transpl. 2002;8:377\u201386.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR18","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.4049\/jimmunol.149.8.2668","volume":"149","author":"K Nomoto","year":"1992","unstructured":"Nomoto K, Eto M, Yanaga K, Nishimura Y, Maeda T, Nomoto K. Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol. 1992;149:2668\u201374.","journal-title":"J Immunol"},{"key":"1246_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"AM Raiola","year":"2013","unstructured":"Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transpl. 2013;19:117\u201322. https:\/\/doi.org\/10.1016\/j.bbmt.2012.08.014","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","volume":"24","author":"P Chiusolo","year":"2018","unstructured":"Chiusolo P, Bug G, Olivieri A, Brune M, Mordini N, Alessandrino PE, et al. A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study. Biol Blood Marrow Transpl. 2018;24:1243\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.031","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR21","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","volume":"26","author":"A Ruggeri","year":"2020","unstructured":"Ruggeri A, Labopin M, Battipaglia G, Chiusolo P, Tischer J, Diez-Martin JL, et al. Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:1915\u201322. https:\/\/doi.org\/10.1016\/j.bbmt.2020.06.026","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR22","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1038\/bmt.2015.93","volume":"50","author":"A Bacigalupo","year":"2015","unstructured":"Bacigalupo A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update. Bone Marrow Transpl. 2015;50:S37\u201339. https:\/\/doi.org\/10.1038\/bmt.2015.93","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.hemonc.2020.01.003","volume":"13","author":"D Medina","year":"2020","unstructured":"Medina D, Estacio M, Rosales M, Manzi E. Haploidentical stem cell transplant with post-transplantation cyclophosphamide and mini-dose methotrexate in children. Hematol Oncol Stem Cell Ther. 2020;13:208\u201313. https:\/\/doi.org\/10.1016\/j.hemonc.2020.01.003","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1246_CR24","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","volume":"21","author":"KF Bradstock","year":"2015","unstructured":"Bradstock KF, Bilmon I, Kwan J, Micklethwaite K, Blyth E, Deren S, et al. Single-Agent High-Dose Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Human Leukocyte Antigen-Matched Reduced-Intensity Peripheral Blood Stem Cell Transplantation Results in an Unacceptably High Rate of Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transpl. 2015;21:941\u20134. https:\/\/doi.org\/10.1016\/j.bbmt.2015.01.020","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/14653240701644000","volume":"9","author":"S Chaleff","year":"2007","unstructured":"Chaleff S, Otto M, Barfield RC, Leimig T, Iyengar R, Martin J, et al. A large-scale method for the selective depletion of alphabeta T lymphocytes from PBSC for allogeneic transplantation. Cytotherapy. 2007;9:746\u201354. https:\/\/doi.org\/10.1080\/14653240701644000","journal-title":"Cytotherapy"},{"key":"1246_CR26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1189\/jlb.0613343","volume":"94","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Merli P, Rutella S. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol. 2013;94:1141\u201357. https:\/\/doi.org\/10.1189\/jlb.0613343","journal-title":"J Leukoc Biol"},{"key":"1246_CR27","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","volume":"110","author":"L Ruggeri","year":"2007","unstructured":"Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433\u201340. https:\/\/doi.org\/10.1182\/blood-2006-07-038687","journal-title":"Blood"},{"key":"1246_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout P, Hayday A. Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol. 2013;13:88\u2013100. https:\/\/doi.org\/10.1038\/nri3384","journal-title":"Nat Rev Immunol"},{"key":"1246_CR29","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726\u201336. https:\/\/doi.org\/10.1038\/nri2395","journal-title":"Nat Rev Immunol"},{"key":"1246_CR30","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","volume":"119","author":"S Arai","year":"2012","unstructured":"Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119:6145\u201354. https:\/\/doi.org\/10.1182\/blood-2011-12-395970","journal-title":"Blood"},{"key":"1246_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1182\/bloodadvances.2017012005","volume":"2","author":"J Gaziev","year":"2018","unstructured":"Gaziev J, Isgro A, Sodani P, Paciaroni K, De Angelis G, Marziali M, et al. Haploidentical HSCT for hemoglobinopathies: improved outcomes with TCRalphabeta(+)\/CD19(+)-depleted grafts. Blood Adv. 2018;2:263\u201370. https:\/\/doi.org\/10.1182\/bloodadvances.2017012005","journal-title":"Blood Adv"},{"key":"1246_CR32","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl J Med. 2011;365:1673\u201383. https:\/\/doi.org\/10.1056\/NEJMoa1106152","journal-title":"N. Engl J Med"},{"key":"1246_CR33","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.bbmt.2018.12.082","volume":"25","author":"F Galaverna","year":"2019","unstructured":"Galaverna F, Ruggeri A, Merli P, Kapoor N, Agarwal-Hashmi R, Aquino V, et al. Administration of BPX-501 Cells Following Ab T and B-Cell-Depleted HLA Haploidentical HSCT (Haplo-HSCT) in Children with Acute Leukemias (AL). ASBMT, 2019. Biol Blood Marrow Transpl. 2019;25:S15.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1172\/JCI17601","volume":"112","author":"BE Anderson","year":"2003","unstructured":"Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Investig. 2003;112:101\u20138. https:\/\/doi.org\/10.1172\/JCI17601","journal-title":"J Clin Investig"},{"key":"1246_CR35","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.4049\/jimmunol.0802212","volume":"182","author":"H Zheng","year":"2009","unstructured":"Zheng H, Matte-Martone C, Jain D, McNiff J, Shlomchik WD. Central memory CD8+ T cells induce graft-versus-host disease and mediate graft-versus-leukemia. J Immunol. 2009;182:5938\u201348. https:\/\/doi.org\/10.4049\/jimmunol.0802212","journal-title":"J Immunol"},{"key":"1246_CR36","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1182\/blood-2006-04-016410","volume":"109","author":"BJ Chen","year":"2007","unstructured":"Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF, et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood. 2007;109:3115\u201323. https:\/\/doi.org\/10.1182\/blood-2006-04-016410","journal-title":"Blood"},{"key":"1246_CR37","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1182\/blood-2009-12-260539","volume":"115","author":"M Bleakley","year":"2010","unstructured":"Bleakley M, Otterud BE, Richardt JL, Mollerup AD, Hudecek M, Nishida T, et al. Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells. Blood. 2010;115:4923\u201333. https:\/\/doi.org\/10.1182\/blood-2009-12-260539","journal-title":"Blood"},{"key":"1246_CR38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.bbmt.2014.01.032","volume":"20","author":"M Bleakley","year":"2014","unstructured":"Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, et al. Engineering human peripheral blood stem cell grafts that are depleted of naive T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transpl. 2014;20:705\u201316. https:\/\/doi.org\/10.1016\/j.bbmt.2014.01.032","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR39","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cyto.a.20643","volume":"73","author":"V Appay","year":"2008","unstructured":"Appay V, van Lier RA, Sallusto F, Roederer M. Phenotype and function of human T lymphocyte subsets: consensus and issues. Cytom A. 2008;73:975\u201383. https:\/\/doi.org\/10.1002\/cyto.a.20643","journal-title":"Cytom A"},{"key":"1246_CR40","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.3389\/fimmu.2019.02516","volume":"10","author":"YJ Chang","year":"2019","unstructured":"Chang YJ, Zhao XY, Huang XJ. Granulocyte colony-stimulating factor-primed unmanipulated haploidentical blood and marrow transplantation. Front Immunol. 2019;10:2516 https:\/\/doi.org\/10.3389\/fimmu.2019.02516","journal-title":"Front Immunol"},{"key":"1246_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbmt.2008.11.025","volume":"15","author":"XJ Huang","year":"2009","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transpl. 2009;15:257\u201365. https:\/\/doi.org\/10.1016\/j.bbmt.2008.11.025","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR42","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/bmt.2008.267","volume":"43","author":"XH Luo","year":"2009","unstructured":"Luo XH, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ. The impact of graft composition on clinical outcomes in unmanipulated HLA-mismatched\/haploidentical hematopoietic SCT. Bone Marrow Transpl. 2009;43:29\u201336. https:\/\/doi.org\/10.1038\/bmt.2008.267","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/bmt.2009.73","volume":"44","author":"XY Zhao","year":"2009","unstructured":"Zhao XY, Chang YJ, Xu LP, Liu DH, Liu KY, Huang XJ. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Bone Marrow Transpl. 2009;44:721\u20138. https:\/\/doi.org\/10.1038\/bmt.2009.73","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR44","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2015.63.8817","volume":"34","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol. 2016;34:1855\u201363. https:\/\/doi.org\/10.1200\/JCO.2015.63.8817","journal-title":"J Clin Oncol"},{"key":"1246_CR45","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1182\/blood-2011-09-380386","volume":"119","author":"CH Yan","year":"2012","unstructured":"Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256\u201362. https:\/\/doi.org\/10.1182\/blood-2011-09-380386","journal-title":"Blood"},{"key":"1246_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-016-0265-2","volume":"9","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Luznik L, Fuchs EJ, Huang XJ. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol Oncol. 2016;9:35 https:\/\/doi.org\/10.1186\/s13045-016-0265-2","journal-title":"J Hematol Oncol"},{"key":"1246_CR47","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1182\/blood-2012-08-453399","volume":"121","author":"P Di Bartolomeo","year":"2013","unstructured":"Di Bartolomeo P, Santarone S, De Angelis G, Picardi A, Cudillo L, Cerretti R, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood. 2013;121:849\u201357. https:\/\/doi.org\/10.1182\/blood-2012-08-453399","journal-title":"Blood"},{"key":"1246_CR48","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/j.bbmt.2019.07.027","volume":"25","author":"PH Imus","year":"2019","unstructured":"Imus PH, Blackford AL, Bettinotti M, Luznik L, Fuchs EJ, Huff CA, et al. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transpl. 2019;25:2431\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2019.07.027","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/cam4.2607","volume":"9","author":"J Mariotti","year":"2020","unstructured":"Mariotti J, Taurino D, Marino F, Bramanti S, Sarina B, Morabito L, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2020;9:52\u201361. https:\/\/doi.org\/10.1002\/cam4.2607","journal-title":"Cancer Med"},{"key":"1246_CR50","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/j.bbmt.2018.06.034","volume":"24","author":"KT Hong","year":"2018","unstructured":"Hong KT, Kang HJ, Choi JY, Hong CR, Cheon JE, Park JD, et al. Favorable outcome of post-transplantation cyclophosphamide haploidentical peripheral blood stem cell transplantation with targeted busulfan-based myeloablative conditioning using intensive pharmacokinetic monitoring in pediatric patients. Biol Blood Marrow Transpl. 2018;24:2239\u201344. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.034","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR51","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bbmt.2015.11.010","volume":"22","author":"SR Jaiswal","year":"2016","unstructured":"Jaiswal SR, Chakrabarti A, Chatterjee S, Bhargava S, Ray K, O\u2019Donnell P, et al. Haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in children with advanced acute leukemia with fludarabine-, busulfan-, and melphalan-based conditioning. Biol Blood Marrow Transpl. 2016;22:499\u2013504. https:\/\/doi.org\/10.1016\/j.bbmt.2015.11.010","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","volume":"22","author":"OR Klein","year":"2016","unstructured":"Klein OR, Chen AR, Gamper C, Loeb D, Zambidis E, Llosa N, et al. Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders. Biol Blood Marrow Transpl. 2016;22:895\u2013901. https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.001","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.bbmt.2016.11.006","volume":"23","author":"C Bonfim","year":"2017","unstructured":"Bonfim C, Ribeiro L, Nichele S, Loth G, Bitencourt M, Koliski A, et al. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide for children and adolescents with fanconi anemia. Biol Blood Marrow Transpl. 2017;23:310\u20137. https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.006","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR54","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1111\/tid.12455","volume":"17","author":"A Ruggeri","year":"2015","unstructured":"Ruggeri A, Roth-Guepin G, Battipaglia G, Mamez AC, Malard F, Gomez A, et al. Incidence and risk factors for hemorrhagic cystitis in unmanipulated haploidentical transplant recipients. Transpl Infect Dis. 2015;17:822\u201330. https:\/\/doi.org\/10.1111\/tid.12455","journal-title":"Transpl Infect Dis"},{"key":"1246_CR55","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","volume":"4","author":"HJ Symons","year":"2020","unstructured":"Symons HJ, Zahurak M, Cao Y, Chen A, Cooke K, Gamper C, et al. Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. Blood Adv. 2020;4:3913\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2020001648","journal-title":"Blood Adv"},{"key":"1246_CR56","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/pbc.10451","volume":"42","author":"LS Kersun","year":"2004","unstructured":"Kersun LS, Wimmer RS, Hoot AC, Meadows AT. Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer. 2004;42:289\u201391. https:\/\/doi.org\/10.1002\/pbc.10451","journal-title":"Pediatr Blood Cancer"},{"key":"1246_CR57","first-page":"1931","volume":"130","author":"S Katewa","year":"2017","unstructured":"Katewa S, Kharya G, Karnik L, Kassim AA, de la Fuente J. Pre-transplantation suppression of haemopoiesis is associated with a high rate of macrophage activation syndrome in Ptcy haploidentical transplantation for haemoglobinopathies. Blood. 2017;130:1931\u20131931.","journal-title":"Blood"},{"key":"1246_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s12185-015-1905-y","volume":"103","author":"SR Jaiswal","year":"2016","unstructured":"Jaiswal SR, Chakrabarti A, Chatterjee S, Bhargava S, Ray K, Chakrabarti S. Hemophagocytic syndrome following haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Int J Hematol. 2016;103:234\u201342. https:\/\/doi.org\/10.1007\/s12185-015-1905-y","journal-title":"Int J Hematol"},{"key":"1246_CR59","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000497074","volume":"46","author":"E Haastrup","year":"2019","unstructured":"Haastrup E, Ifversen MRS, Heilmann C, Fischer-Nielsen A. Depletion of alphabeta+ T and B cells using the CliniMACS prodigy: results of 10 graft-processing procedures from haploidentical donors. Transfus Med Hemother. 2019;46:446\u20139. https:\/\/doi.org\/10.1159\/000497074","journal-title":"Transfus Med Hemother"},{"key":"1246_CR60","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","volume":"132","author":"A Bertaina","year":"2018","unstructured":"Bertaina A, Zecca M, Buldini B, Sacchi N, Algeri M, Saglio F, et al. Unrelated donor vs HLA-haploidentical alpha\/beta T-cell and B-cell depleted HSCT in children with acute leukemia. Blood. 2018;132:2594\u2013607. https:\/\/doi.org\/10.1182\/blood-2018-07-861575","journal-title":"Blood"},{"key":"1246_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaci.2019.01.030","volume":"144","author":"R Elfeky","year":"2019","unstructured":"Elfeky R, Shah RM, Unni MNM, Ottaviano G, Rao K, Chiesa R, et al. New graft manipulation strategies improve the outcome of mismatched stem cell transplantation in children with primary immunodeficiencies. J Allergy Clin Immunol. 2019;144:280\u201393. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.030","journal-title":"J Allergy Clin Immunol"},{"key":"1246_CR62","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1016\/j.bbmt.2015.07.008","volume":"21","author":"D Balashov","year":"2015","unstructured":"Balashov D, Shcherbina A, Maschan M, Trakhtman P, Skvortsova Y, Shelikhova L, et al. Single-center experience of unrelated and haploidentical stem cell transplantation with TCRalphabeta and CD19 depletion in children with primary immunodeficiency syndromes. Biol Blood Marrow Transpl. 2015;21:1955\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.008","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR63","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3109\/08880018.2014.961214","volume":"31","author":"A Sawada","year":"2014","unstructured":"Sawada A, Shimizu M, Isaka K, Higuchi K, Mayumi A, Yoshimoto Y, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies. Pediatr Hematol Oncol. 2014;31:754\u201364. https:\/\/doi.org\/10.3109\/08880018.2014.961214","journal-title":"Pediatr Hematol Oncol"},{"key":"1246_CR64","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.bbmt.2016.11.016","volume":"23","author":"OR Klein","year":"2017","unstructured":"Klein OR, Buddenbaum J, Tucker N, Chen AR, Gamper CJ, Loeb D, et al. Nonmyeloablative haploidentical bone marrow transplantation with post-transplantation cyclophosphamide for pediatric and young adult patients with high-risk hematologic malignancies. Biol Blood Marrow Transpl. 2017;23:325\u201332. https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.016","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR65","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/bmt.2016.161","volume":"51","author":"G Dufort","year":"2016","unstructured":"Dufort G, Castillo L, Pisano S, Castiglioni M, Carolina P, Andrea I, et al. Haploidentical hematopoietic stem cell transplantation in children with high-risk hematologic malignancies: outcomes with two different strategies for GvHD prevention. Ex vivo T-cell depletion and post-transplant cyclophosphamide: 10 years of experience at a single center. Bone Marrow Transpl. 2016;51:1354\u201360. https:\/\/doi.org\/10.1038\/bmt.2016.161","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR66","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","volume":"21","author":"SR Solomon","year":"2015","unstructured":"Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, et al. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biol Blood Marrow Transpl. 2015;21:1299\u2013307. https:\/\/doi.org\/10.1016\/j.bbmt.2015.03.003","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR67","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fped.2020.00282","volume":"8","author":"E Katsanis","year":"2020","unstructured":"Katsanis E, Sapp LN, Reid SC, Reddivalla N, Stea B. T-cell replete myeloablative haploidentical bone marrow transplantation is an effective option for pediatric and young adult patients with high-risk hematologic malignancies. Front Pediatr. 2020;8:282 https:\/\/doi.org\/10.3389\/fped.2020.00282","journal-title":"Front Pediatr"},{"key":"1246_CR68","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbmt.2018.06.007","volume":"24","author":"E Katsanis","year":"2018","unstructured":"Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide\/bendamustine in pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transpl. 2018;24:2034\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.007","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR69","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1182\/blood-2018-99-115083","volume":"132","author":"G Lopez-Hernandez","year":"2018","unstructured":"Lopez-Hernandez G, Lopez-Santiago N, Olaya-Vargas A, P\u00e9rez-Garc\u00eda M, Ram\u00edrez-Uribe RMN, Salazar-Rosales HdP, et al. Haploidentical stem cell transplantation with post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in pediatric hematologic malignancies. Blood. 2018;132:5705\u20135705. https:\/\/doi.org\/10.1182\/blood-2018-99-115083","journal-title":"Blood"},{"key":"1246_CR70","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.bbmt.2016.02.002","volume":"22","author":"M Berger","year":"2016","unstructured":"Berger M, Lanino E, Cesaro S, Zecca M, Vassallo E, Faraci M, et al. Feasibility and outcome of haploidentical hematopoietic stem cell transplantation with post-transplant high-dose cyclophosphamide for children and adolescents with hematologic malignancies: an AIEOP-GITMO retrospective multicenter study. Biol Blood Marrow Transpl. 2016;22:902\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.002","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR71","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbmt.2012.12.005","volume":"19","author":"P Satwani","year":"2013","unstructured":"Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transpl. 2013;19:552\u201361. https:\/\/doi.org\/10.1016\/j.bbmt.2012.12.005","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR72","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1038\/bmt.2015.87","volume":"50","author":"P Lang","year":"2015","unstructured":"Lang P, Feuchtinger T, Teltschik HM, Schwinger W, Schlegel P, Pfeiffer M, et al. Improved immune recovery after transplantation of TCRalphabeta\/CD19-depleted allografts from haploidentical donors in pediatric patients. Bone Marrow Transpl. 2015;50:S6\u201310. https:\/\/doi.org\/10.1038\/bmt.2015.87","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR73","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2017-01-759258","volume":"130","author":"PJ Lang","year":"2017","unstructured":"Lang PJ, Schlegel PG, Meisel R, Schulz AS, Greil J, Bader P, et al. Safety and efficacy of Tcralpha\/Beta and CD19 depleted haploidentical stem cell transplantation following reduced intensity conditioning in children: results of a prospective multicenter phase I\/II clinical trial. Blood. 2017;130:214\u2013214.","journal-title":"Blood"},{"key":"1246_CR74","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.bbmt.2019.01.023","volume":"25","author":"L Shelikhova","year":"2019","unstructured":"Shelikhova L, Ilushina M, Shekhovtsova Z, Shasheleva D, Khismatullina R, Kurnikova E, et al. Alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation without antithymocyte globulin in children with chemorefractory acute myelogenous leukemia. Biol Blood Marrow Transpl. 2019;25:e179\u2013e182. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.023","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR75","doi-asserted-by":"publisher","unstructured":"Jacoby E, Varda-Bloom N, Goldstein G, Hutt D, Churi C, Vernitsky H et al. Comparison of two cytoreductive regimens for alphabeta-T-cell-depleted haploidentical HSCT in pediatric malignancies: Improved engraftment and outcome with TBI-based regimen. Pediatr Blood Cancer. 2018;65. https:\/\/doi.org\/10.1002\/pbc.26839","DOI":"10.1002\/pbc.26839"},{"key":"1246_CR76","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41409-019-0607-0","volume":"54","author":"B Bielorai","year":"2019","unstructured":"Bielorai B, Jacoby E, Varda-Bloom N, Hutt D, Churi C, Vernitsky H, et al. Haploidentical hematopoietic stem cell transplantation with alphabetaTCR+\/CD19+ depletion in pediatric patients with malignant and non-malignant disorders. Bone Marrow Transpl. 2019;54:694\u20137. https:\/\/doi.org\/10.1038\/s41409-019-0607-0","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR77","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","volume":"130","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. Blood. 2017;130:677\u201385. https:\/\/doi.org\/10.1182\/blood-2017-04-779769","journal-title":"Blood"},{"key":"1246_CR78","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood-2018-99-117136","volume":"132","author":"P Merli","year":"2018","unstructured":"Merli P, Algeri M, Li Pira G, Falco M, Pende D, Bertaina V, et al. Alpha\/beta T-cell and B-cell depletion HLA-haploidentical hematopoietic stem cell transplantation is an effective treatment for children\/young adults with acute leukemia. Blood. 2018;132:2169\u20132169. https:\/\/doi.org\/10.1182\/blood-2018-99-117136","journal-title":"Blood"},{"key":"1246_CR79","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1182\/blood.V128.22.4672.4672","volume":"128","author":"L Shelikhova","year":"2016","unstructured":"Shelikhova L, Shekhovtsova Z, Balashov D, Boyakova E, Muzalevskyi I, Gutovskaya E, et al. Tcr\u03b1\u03b2+\/CD19+-depletion in hematopoietic stem cells transplantation from matched unrelated and haploidentical donors following treosulfan or TBI-based conditioning in pediatric acute lymphoblastic leukemia patients. Blood. 2016;128:4672\u20134672.","journal-title":"Blood"},{"key":"1246_CR80","first-page":"4580","volume":"130","author":"L Shelikhova","year":"2017","unstructured":"Shelikhova L, Ilushina M, Shekhovtsova Z, Kurnikova E, Novichkova G, Maschan A, et al. Alpha\/Beta T cell depleted haploidentical transplantation results in high survival in pediatric patients with acute myeloid leukemia. ASH; Atlanta, GA. Blood. 2017;130:4580.","journal-title":"Blood"},{"key":"1246_CR81","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.bbmt.2008.02.007","volume":"14","author":"D Liu","year":"2008","unstructured":"Liu D, Huang X, Liu K, Xu L, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children. Biol Blood Marrow Transpl. 2008;14:469\u201377. https:\/\/doi.org\/10.1016\/j.bbmt.2008.02.007","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR82","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/bmt.2013.99","volume":"48","author":"DH Liu","year":"2013","unstructured":"Liu DH, Xu LP, Liu KY, Wang Y, Chen H, Han W, et al. Long-term outcomes of unmanipulated haploidentical HSCT for paediatric patients with acute leukaemia. Bone Marrow Transpl. 2013;48:1519\u201324. https:\/\/doi.org\/10.1038\/bmt.2013.99","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR83","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-020-00860-y","volume":"13","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wang Y, Xu LP, Zhang XH, Chen H, Chen YH, et al. Haploidentical donor is preferred over matched sibling donor for pre-transplantation MRD positive ALL: a phase 3 genetically randomized study. J Hematol Oncol. 2020;13:27. https:\/\/doi.org\/10.1186\/s13045-020-00860-y","journal-title":"J Hematol Oncol"},{"key":"1246_CR84","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/bjh.16226","volume":"188","author":"YJ Xue","year":"2020","unstructured":"Xue YJ, Suo P, Huang XJ, Lu AD, Wang Y, Zuo YX, et al. Superior survival of unmanipulated haploidentical haematopoietic stem cell transplantation compared with intensive chemotherapy as post-remission treatment for children with very high-risk philadelphia chromosome negative B-cell acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2020;188:757\u201367. https:\/\/doi.org\/10.1111\/bjh.16226","journal-title":"Br J Haematol"},{"key":"1246_CR85","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.bbmt.2018.12.007","volume":"25","author":"YJ Xue","year":"2019","unstructured":"Xue YJ, Cheng YF, Lu AD, Wang Y, Zuo YX, Yan CH, et al. Allogeneic hematopoietic stem cell transplantation, especially haploidentical, may improve long-term survival for high-risk pediatric patients with philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era. Biol Blood Marrow Transpl. 2019;25:1611\u201320. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.007","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR86","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134. https:\/\/doi.org\/10.1186\/s13045-017-0502-3","journal-title":"J Hematol Oncol"},{"key":"1246_CR87","first-page":"4563","volume":"130","author":"AM Trujillo","year":"2017","unstructured":"Trujillo AM, Karduss AJ, Suarez G, Perez R, Ruiz G, Cardona A, et al. Long term follow up of haploidentical peripheral blood stem cell transplantation with post-transplant cyclophosphamide in children and teenagers <18 years old with high-risk acute leukemia. very good results in CR1 and CR2 patients but unexpected high incidence of severe acute graft versus host disease in children <10 years. ASH; 7 december 2017. Blood. 2017;130:4563.","journal-title":"Blood"},{"key":"1246_CR88","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","volume":"120","author":"J Bolanos-Meade","year":"2012","unstructured":"Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood. 2012;120:4285\u201391. https:\/\/doi.org\/10.1182\/blood-2012-07-438408","journal-title":"Blood"},{"key":"1246_CR89","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.bbmt.2014.03.003","volume":"20","author":"K Raj","year":"2014","unstructured":"Raj K, Pagliuca A, Bradstock K, Noriega V, Potter V, Streetly M, et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transpl. 2014;20:890\u20135. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.003","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR90","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/bmt.2015.343","volume":"51","author":"M Maschan","year":"2016","unstructured":"Maschan M, Shelikhova L, Ilushina M, Kurnikova E, Boyakova E, Balashov D, et al. TCR-alpha\/beta and CD19 depletion and treosulfan-based conditioning regimen in unrelated and haploidentical transplantation in children with acute myeloid leukemia. Bone Marrow Transpl. 2016;51:668\u201374. https:\/\/doi.org\/10.1038\/bmt.2015.343","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41409-019-0531-3","volume":"55","author":"M Maschan","year":"2020","unstructured":"Maschan M, Shelikhova L, Ilushina M, Shekhovtsova Z, Khismatullina R, Kurnikova E, et al. Outcome of alphabeta T cell-depleted transplantation in children with high-risk acute myeloid leukemia, grafted in remission. Bone Marrow Transpl. 2020;55:256\u20139. https:\/\/doi.org\/10.1038\/s41409-019-0531-3","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR92","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1172\/JCI81229","volume":"125","author":"M Bleakley","year":"2015","unstructured":"Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Investig. 2015;125:2677\u201389. https:\/\/doi.org\/10.1172\/JCI81229","journal-title":"J Clin Investig"},{"key":"1246_CR93","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/bmt.2015.139","volume":"50","author":"BM Triplett","year":"2015","unstructured":"Triplett BM, Shook DR, Eldridge P, Li Y, Kang G, Dallas M, et al. Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. Bone Marrow Transpl. 2015;50:1012. https:\/\/doi.org\/10.1038\/bmt.2015.139","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR94","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1038\/s41409-019-0750-7","volume":"55","author":"E Mamcarz","year":"2020","unstructured":"Mamcarz E, Madden R, Qudeimat A, Srinivasan A, Talleur A, Sharma A, et al. Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transpl. 2020;55:929\u201338. https:\/\/doi.org\/10.1038\/s41409-019-0750-7","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR95","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/ajh.25661","volume":"95","author":"A Perez-Martinez","year":"2020","unstructured":"Perez-Martinez A, Ferreras C, Pascual A, Gonzalez-Vicent M, Alonso L, Badell I, et al. Haploidentical transplantation in high-risk pediatric leukemia: a retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020;95:28\u201337. https:\/\/doi.org\/10.1002\/ajh.25661","journal-title":"Am J Hematol"},{"key":"1246_CR96","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/cac2.12014","volume":"40","author":"FM Zheng","year":"2020","unstructured":"Zheng FM, Zhang X, Li CF, Cheng YF, Gao L, He YL, et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study. Cancer Commun (Lond). 2020;40:93\u2013104. https:\/\/doi.org\/10.1002\/cac2.12014","journal-title":"Cancer Commun (Lond)"},{"key":"1246_CR97","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bmt.1705445","volume":"38","author":"XJ Huang","year":"2006","unstructured":"Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transpl. 2006;38:291\u20137. https:\/\/doi.org\/10.1038\/sj.bmt.1705445","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR98","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1038\/bmt.2015.91","volume":"50","author":"W Arcese","year":"2015","unstructured":"Arcese W, Picardi A, Santarone S, De Angelis G, Cerretti R, Cudillo L, et al. Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update. Bone Marrow Transpl. 2015;50:S24\u201330. https:\/\/doi.org\/10.1038\/bmt.2015.91","journal-title":"Bone Marrow Transpl"},{"key":"1246_CR99","doi-asserted-by":"publisher","first-page":"e1356152","DOI":"10.1080\/2162402X.2017.1356152","volume":"6","author":"Y Wang","year":"2017","unstructured":"Wang Y, Chang YJ, Chen L, Xu LP, Bian ZL, Zhang XH, et al. Low-dose post-transplant cyclophosphamide can mitigate GVHD and enhance the G-CSF\/ATG induced GVHD protective activity and improve haploidentical transplant outcomes. Oncoimmunology. 2017;6:e1356152. https:\/\/doi.org\/10.1080\/2162402X.2017.1356152","journal-title":"Oncoimmunology"},{"key":"1246_CR100","doi-asserted-by":"publisher","first-page":"e86252","DOI":"10.1172\/jci.insight.86252","volume":"1","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Coffey DG, Towlerton AM, Vulic A, Storer BE, Chou J, et al. Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight. 2016;1:e86252. https:\/\/doi.org\/10.1172\/jci.insight.86252","journal-title":"JCI Insight"},{"key":"1246_CR101","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.bbmt.2017.03.016","volume":"23","author":"NN Shah","year":"2017","unstructured":"Shah NN, Freeman AF, Su H, Cole K, Parta M, Moutsopoulos NM, et al. Haploidentical related donor hematopoietic stem cell transplantation for dedicator-of-cytokinesis 8 deficiency using post-transplantation cyclophosphamide. Biol Blood Marrow Transpl. 2017;23:980\u201390. https:\/\/doi.org\/10.1016\/j.bbmt.2017.03.016","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR102","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3324\/haematol.2017.186619","volume":"103","author":"A Roberto","year":"2018","unstructured":"Roberto A, Di Vito C, Zaghi E, Mazza EMC, Capucetti A, Calvi M, et al. The early expansion of anergic NKG2A(pos)\/CD56(dim)\/CD16(neg) natural killer represents a therapeutic target in haploidentical hematopoietic stem cell transplantation. Haematologica. 2018;103:1390\u2013402. https:\/\/doi.org\/10.3324\/haematol.2017.186619","journal-title":"Haematologica"},{"key":"1246_CR103","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","volume":"118","author":"CG Brunstein","year":"2011","unstructured":"Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282\u20138. https:\/\/doi.org\/10.1182\/blood-2011-03-344853","journal-title":"Blood"},{"key":"1246_CR104","doi-asserted-by":"publisher","first-page":"e1342024","DOI":"10.1080\/2162402X.2017.1342024","volume":"6","author":"H Stabile","year":"2017","unstructured":"Stabile H, Nisti P, Peruzzi G, Fionda C, Pagliara D, Brescia PL, et al. Reconstitution of multifunctional CD56(low)CD16(low) natural killer cell subset in children with acute leukemia given alpha\/beta T cell-depleted HLA-haploidentical haematopoietic stem cell transplantation. Oncoimmunology. 2017;6:e1342024. https:\/\/doi.org\/10.1080\/2162402X.2017.1342024","journal-title":"Oncoimmunology"},{"key":"1246_CR105","doi-asserted-by":"publisher","first-page":"e1216291","DOI":"10.1080\/2162402X.2016.1216291","volume":"6","author":"A Bertaina","year":"2017","unstructured":"Bertaina A, Zorzoli A, Petretto A, Barbarito G, Inglese E, Merli P, et al. Zoledronic acid boosts gammadelta T-cell activity in children receiving alphabeta(+) T and CD19(+) cell-depleted grafts from an HLA-haplo-identical donor. Oncoimmunology. 2017;6:e1216291. https:\/\/doi.org\/10.1080\/2162402X.2016.1216291","journal-title":"Oncoimmunology"},{"key":"1246_CR106","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1007\/s00262-005-0094-6","volume":"55","author":"PF Meeh","year":"2006","unstructured":"Meeh PF, King M, O\u2019Brien RL, Muga S, Buckhalts P, Neuberg R, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006;55:1072\u201380. https:\/\/doi.org\/10.1007\/s00262-005-0094-6","journal-title":"Cancer Immunol Immunother"},{"key":"1246_CR107","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2018.04.009","volume":"39","author":"F Locatelli","year":"2018","unstructured":"Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L. NK cells mediate a crucial graft-versus-leukemia effect in haploidentical-HSCT to cure high-risk acute leukemia. Trends Immunol. 2018;39:577\u201390. https:\/\/doi.org\/10.1016\/j.it.2018.04.009","journal-title":"Trends Immunol"},{"key":"1246_CR108","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3389\/fimmu.2020.02022","volume":"11","author":"F Gao","year":"2020","unstructured":"Gao F, Ye Y, Gao Y, Huang H, Zhao Y. Influence of KIR and NK cell reconstitution in the outcomes of hematopoietic stem cell transplantation. Front Immunol. 2020;11:2022. https:\/\/doi.org\/10.3389\/fimmu.2020.02022","journal-title":"Front Immunol"},{"key":"1246_CR109","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/sj.leu.2404566","volume":"21","author":"XJ Huang","year":"2007","unstructured":"Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia. 2007;21:848\u201351. https:\/\/doi.org\/10.1038\/sj.leu.2404566","journal-title":"Leukemia"},{"key":"1246_CR110","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","volume":"24","author":"A Wanquet","year":"2018","unstructured":"Wanquet A, Bramanti S, Harbi S, Furst S, Legrand F, Faucher C, et al. Killer cell immunoglobulin-like receptor-ligand mismatch in donor versus recipient direction provides better graft-versus-tumor effect in patients with hematologic malignancies undergoing allogeneic T cell-replete haploidentical transplantation followed by post-transplant cyclophosphamide. Biol Blood Marrow Transpl. 2018;24:549\u201354. https:\/\/doi.org\/10.1016\/j.bbmt.2017.11.042","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR111","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41375-018-0170-5","volume":"33","author":"A Shimoni","year":"2018","unstructured":"Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, G\u00fclbas Z, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018;33:230\u20139. https:\/\/doi.org\/10.1038\/s41375-018-0170-5","journal-title":"Leukemia"},{"key":"1246_CR112","doi-asserted-by":"publisher","first-page":"E659","DOI":"10.1002\/ajh.24910","volume":"92","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Zhao XS, Wang Y, Liu YR, Xu LP, Zhang XH, et al. Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. Am J Hematol. 2017;92:E659\u2013E661. https:\/\/doi.org\/10.1002\/ajh.24910","journal-title":"Am J Hematol"},{"key":"1246_CR113","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/j.bbmt.2016.09.004","volume":"22","author":"XD Mo","year":"2016","unstructured":"Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Unmanipulated haploidentical hematopoietic stem cell transplantation in first complete remission can abrogate the poor outcomes of children with acute myeloid leukemia resistant to the first course of induction chemotherapy. Biol Blood Marrow Transpl. 2016;22:2235\u201342. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.004","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR114","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.bbmt.2020.05.021","volume":"26","author":"FF Tang","year":"2020","unstructured":"Tang FF, Cheng YF, Xu LP, Zhang XH, Yan CH, Han W, et al. Incidence, risk factors, and outcomes of chronic graft-versus-host disease in pediatric patients with hematologic malignancies after T cell-replete myeloablative haploidentical hematopoietic stem cell transplantation with antithymocyte globulin\/granulocyte colony-stimulating factor. Biol Blood Marrow Transpl. 2020;26:1655\u201362. https:\/\/doi.org\/10.1016\/j.bbmt.2020.05.021","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR115","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fimmu.2020.00147","volume":"11","author":"PE Rovatti","year":"2020","unstructured":"Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation. Front Immunol. 2020;11:147. https:\/\/doi.org\/10.3389\/fimmu.2020.00147","journal-title":"Front Immunol"},{"key":"1246_CR116","doi-asserted-by":"publisher","first-page":"e16498","DOI":"10.1097\/MD.0000000000016498","volume":"98","author":"C Zhang","year":"2019","unstructured":"Zhang C, Ma YY, Liu J, Liu Y, Gao L, Gao L, et al. Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: two cases report. Med (Baltim). 2019;98:e16498. https:\/\/doi.org\/10.1097\/MD.0000000000016498","journal-title":"Med (Baltim)"},{"key":"1246_CR117","doi-asserted-by":"publisher","unstructured":"Wiebking V, Lee CM, Mostrel N, Lahiri P, Bak R, Bao G et al. Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing alphabeta T cell-depleted haploidentical hematopoietic stem cell transplantation. Haematologica. 2020;105. https:\/\/doi.org\/10.3324\/haematol.2019.233882","DOI":"10.3324\/haematol.2019.233882"},{"key":"1246_CR118","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1172\/JCI128710","volume":"130","author":"V Radojcic","year":"2019","unstructured":"Radojcic V, Luznik L. Mechanism of action of posttransplantation cyclophosphamide: more than meets the eye. J Clin Invest. 2019;130:2189\u201391. https:\/\/doi.org\/10.1172\/JCI128710","journal-title":"J Clin Invest"},{"key":"1246_CR119","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/leu.2016.321","volume":"31","author":"IV Zvyagin","year":"2017","unstructured":"Zvyagin IV, Mamedov IZ, Tatarinova OV, Komech EA, Kurnikova EE, Boyakova EV, et al. Tracking T-cell immune reconstitution after TCRalphabeta\/CD19-depleted hematopoietic cells transplantation in children. Leukemia. 2017;31:1145\u201353. https:\/\/doi.org\/10.1038\/leu.2016.321","journal-title":"Leukemia"},{"key":"1246_CR120","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","volume":"6","author":"J Bolanos-Meade","year":"2019","unstructured":"Bolanos-Meade J, Cooke KR, Gamper CJ, Ali SA, Ambinder RF, Borrello IM, et al. Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. Lancet Haematol. 2019;6:e183\u2013e193. https:\/\/doi.org\/10.1016\/S2352-3026(19)30031-6","journal-title":"Lancet Haematol"},{"key":"1246_CR121","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.bbmt.2016.12.635","volume":"23","author":"A Laberko","year":"2017","unstructured":"Laberko A, Bogoyavlenskaya A, Shelikhova L, Shekhovtsova Z, Balashov D, Voronin K, et al. Risk factors for and the clinical impact of cytomegalovirus and Epstein-Barr virus infections in pediatric recipients of TCR-alpha\/beta- and CD19-depleted grafts. Biol Blood Marrow Transpl. 2017;23:483\u201390. https:\/\/doi.org\/10.1016\/j.bbmt.2016.12.635","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR122","doi-asserted-by":"publisher","first-page":"e12823","DOI":"10.1111\/tid.12823","volume":"20","author":"BM Triplett","year":"2018","unstructured":"Triplett BM, Muller B, Kang G, Li Y, Cross SJ, Moen J, et al. Selective T-cell depletion taHaplo-HSCTrgeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion. Transpl Infect Dis. 2018;20:e12823. https:\/\/doi.org\/10.1111\/tid.12823","journal-title":"Transpl Infect Dis"},{"key":"1246_CR123","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.bbmt.2018.07.016","volume":"24","author":"L Sisinni","year":"2018","unstructured":"Sisinni L, Gasior M, de Paz R, Querol S, Bueno D, Fernandez L, et al. Unexpected high incidence of human Herpesvirus-6 encephalitis after naive T cell-depleted graft of haploidentical stem cell transplantation in pediatric patients. Biol Blood Marrow Transpl. 2018;24:2316\u201323. https:\/\/doi.org\/10.1016\/j.bbmt.2018.07.016","journal-title":"Biol Blood Marrow Transpl"},{"key":"1246_CR124","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3389\/fimmu.2019.01342","volume":"10","author":"A Bertaina","year":"2019","unstructured":"Bertaina A, Roncarolo MG. Graft engineering and adoptive immunotherapy: new approaches to promote immune tolerance after hematopoietic stem cell transplantation. Front Immunol. 2019;10:1342. https:\/\/doi.org\/10.3389\/fimmu.2019.01342","journal-title":"Front Immunol"},{"key":"1246_CR125","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/pbc.26131","volume":"63","author":"O Gonzalez-Llano","year":"2016","unstructured":"Gonzalez-Llano O, Gonzalez-Lopez EE, Ramirez-Cazares AC, Marcos-Ramirez ER, Ruiz-Arguelles GJ, Gomez-Almaguer D. Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide in children and adolescents with hematological malignancies. Pediatr Blood Cancer. 2016;63:2033\u20137. https:\/\/doi.org\/10.1002\/pbc.26131","journal-title":"Pediatr Blood Cancer"},{"key":"1246_CR126","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood.V128.22.389.389","volume":"128","author":"PJ Lang","year":"2016","unstructured":"Lang PJ, Schlegel PG, Meisel R, Schulz AS, Greil J, Bader P, et al. TCR-alpha\/beta and CD19 depleted haploidentical stem cell transplantation following reduced intensity conditioning in children: first results of a prospective multicenter phase I\/II clinical trial. Blood. 2016;128:389\u2013389.","journal-title":"Blood"},{"key":"1246_CR127","doi-asserted-by":"publisher","first-page":"e13192","DOI":"10.1111\/petr.13192","volume":"22","author":"F Erbey","year":"2018","unstructured":"Erbey F, Akcay A, Atay D, Ovali E, Ozturk G. Comparison of outcomes after HLA-matched unrelated and alphabeta T-cell-depleted haploidentical hematopoietic stem cell transplantation for children with high-risk acute leukemia. Pediatr Transpl. 2018;22:e13192. https:\/\/doi.org\/10.1111\/petr.13192","journal-title":"Pediatr Transpl"},{"key":"1246_CR128","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.leukres.2017.05.021","volume":"59","author":"H Chen","year":"2017","unstructured":"Chen H, Liu KY, Xu LP, Chen YH, Zhang XH, Wang Y, et al. Haploidentical hematopoietic stem cell transplantation for pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia in the imatinib era. Leuk Res. 2017;59:136\u201341. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.021","journal-title":"Leuk Res"},{"key":"1246_CR129","doi-asserted-by":"publisher","first-page":"106333","DOI":"10.1016\/j.leukres.2020.106333","volume":"91","author":"L Bai","year":"2020","unstructured":"Bai L, Cheng YF, Lu AD, Suo P, Wang Y, Zuo YX, et al. Prognosis of haploidentical hematopoietic stem cell transplantation in non-infant children with t(v;11q23)\/MLL-rearranged B-cell acute lymphoblastic leukemia. Leuk Res. 2020;91:106333. https:\/\/doi.org\/10.1016\/j.leukres.2020.106333","journal-title":"Leuk Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01246-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-021-01246-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:13:19Z","timestamp":1697980399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-021-01246-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,5]]},"references-count":129,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1038\/s41409-021-01246-5","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,5]]},"assertion":[{"value":"23 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}